IC-MPGN clinical trials at UCLA
2 in progress, 1 open to eligible people
Iptacopan in Participants With IC-MPGN
open to eligible people ages 12-60
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Los Angeles, California and other locations
Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Sorry, in progress, not accepting new patients
This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.
Los Angeles, California and other locations
Our lead scientists for IC-MPGN research studies include Lama Abdelnour.
Last updated: